[Statins and the "Cabala": the new Note 13].
The new Note 13 introduces significant changes in the regulation of statin reimbursement. Although cardiovascular risk assessment still plays a key role, cardiovascular risk estimation has shifted from the "risk charts" to the more simple "sum of risk factors". In addition, the new Note 13 expands drug reimbursement to subjects at intermediate risk, who represent the main source of cardiovascular events because of the size of the population. As a consequence, the general trend of the new Note 13 is to simplify the rules that govern statin reimbursement and to guarantee treatment for all subjects at increased risk of cardiac and vascular events.